Skip to content
Therapy But Better – Lifestyle
Author:
Vivace Therapeutics, Inc.
Vivace Therapeutics Strengthens Leadership Team as It Prepares to Advance VT3989, the First TEAD Inhibitor to enter Phase 3 Clinical Trials, as the Leading Treatment for Mesothelioma
August 26, 2026